Sugi Predict

Sugi Predict / Compounds / SCHEMBL2391813

SCHEMBL2391813

SCHEMBL2391813

CCOC(=O)Cc1ccc(OC(C)C)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.53
▸ MAPT P10636 2/20 0.53
▸ MAPK1 P28482 2/20 0.53
▸ ABL1 P00519 1/20 0.52
▸ RIN1 Q13671 1/20 0.52
▸ DRD2 P14416 1/20 0.49
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ P2RX3 P56373 2/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ LDHA P00338 1/20 0.46
▸ CA12 O43570 2/20 0.45
▸ CA1 P00915 2/20 0.45
▸ CA2 P00918 2/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7319318 0.93 ALDH1A1 (0.45) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL2394329 0.89 HDAC1 (0.51) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL2394324 0.89 HDAC1 (0.51) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL908271 0.88 ABL1 (0.59) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL5688167 0.86 CYP4F2 (0.51) ALDH1A1MAPTMAPK1DRD2KMT2A
SCHEMBL897654 0.86 TSHR (0.51) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL3782064 0.84 LMNA (0.55) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL15057261 0.83 ABL1 (0.49) ALDH1A1MAPTMAPK1ABL1RIN1
SCHEMBL2392443 0.82 CA5A (0.62) ALDH1A1MAPTABL1RIN1MEN1
SCHEMBL10245332 0.82 POLB (0.57) ALDH1A1MAPTMAPK1ABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20220411432-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2022-12-29 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
US-11192898-B2 MDM2 protein degraders THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2021-12-07 — — US disclosed
EP-3613729-A1 TETRACYCLIC COMPOUNDS CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-02-26 — — EP disclosed
EP-3345903-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2019-10-09 — — EP disclosed
US-20190127387-A1 MDM2 PROTEIN DEGRADERS UNIV MICHIGAN REGENTS (US) 2019-05-02 — — US disclosed
EP-3345903-A1 TETRACYCLIC COMPOUNDS Chugai Seiyaku Kabushiki Kaisha (JP) 2018-07-11 — — EP disclosed
EP-2975024-B1 TETRACYCLIC COMPOUNDS CHUGAI PHARMACEUTICAL CO LTD (JP) 2018-03-28 — — EP disclosed
WO-2017176957-A1 MDM2 PROTEIN DEGRADERS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2017-10-12 — — WO disclosed
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2012-05-24 — — US disclosed
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2012-05-24 — — US disclosed
WO-2012066095-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
WO-2012066095-A1 CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION NOVARTIS AG (CH) 2012-05-24 — — WO disclosed
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction NOVARTIS AG (CH) 2012-05-24 — — US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones NOVARTIS AG (CH) 2011-09-22 — — US disclosed
WO-2010143664-A1 TETRACYCLIC COMPOUND 中外製薬株式会社 (JP) 2010-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192898-B2 MDM2 protein degraders MDM2, TP53, TP53BP1 ALDH1A1 300/4885MAPT 545/4885MAPK1 1571/4885
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALDH1A1 1165/4885MAPT 68/4885MAPK1 305/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALDH1A1 1165/4885MAPT 68/4885MAPK1 305/4885
US-20110230457-A1 Substituted Isoquinolinones and Quinazolinones MDM4, MDM2, TP53 ALDH1A1 3726/4885MAPT 957/4885MAPK1 1776/4885
US-20220411432-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 ALDH1A1 300/4885MAPT 545/4885MAPK1 1571/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 ALDH1A1 1165/4885MAPT 68/4885MAPK1 305/4885
US-20120129871-A1 Crystalline form of an inhibitor of MDM2/4 and p53 interaction MDM4, TP53, TP53BP1 ALDH1A1 4048/4885MAPT 144/4885MAPK1 1628/4885
US-20190127387-A1 MDM2 PROTEIN DEGRADERS MDM2, TP53, TP53BP1 ALDH1A1 300/4885MAPT 545/4885MAPK1 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.